Compare PMT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMT | CRVS |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.2M | 1.0B |
| IPO Year | N/A | 2016 |
| Metric | PMT | CRVS |
|---|---|---|
| Price | $10.13 | $11.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $13.50 | ★ $30.17 |
| AVG Volume (30 Days) | 851.9K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 13.33% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.55 | N/A |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.83 | $3.55 |
| 52 Week High | $13.80 | $26.95 |
| Indicator | PMT | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 39.86 | 43.85 |
| Support Level | N/A | $11.13 |
| Resistance Level | $12.76 | $14.00 |
| Average True Range (ATR) | 0.23 | 0.63 |
| MACD | 0.04 | 0.15 |
| Stochastic Oscillator | 27.24 | 56.22 |
PennyMac Mortgage Investment Trust is a specialty finance company that invests mainly in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.